Nuvation Bio Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David T. Hung
- Full Time Employees
- 305
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1500 Broadway New York City NY United States of America 10036
- IPO Date
- Aug 26, 2020
- CIK
- 0001811063
- Website
- nuvationbio.com
- Similar Companies
- Business
- Nuvation Bio Inc. is a global biopharmaceutical company specializing in oncology drug development, focused on addressing significant unmet needs in cancer treatment. The company’s core products include taletrectinib (IBTROZI™), an oral, potent, central nervous system-active ROS1 inhibitor for ROS1-positive non-small cell lung cancer; safusidenib, a brain-penetrant, oral targeted inhibitor of mutant IDH1 for gliomas; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer therapy; and NUV-868, a BD2-selective BET inhibitor. Nuvation also develops proprietary DDC technology that selectively delivers potent anti-cancer agents to tumor cells to improve efficacy and reduce toxicity to healthy tissue. Founded in 2018 and headquartered in New York, the company operates additional offices in San Francisco, Boston, and Shanghai. Recent strategic developments include the acquisition of AnHeart Therapeutics in March 2024, enhancing its clinical pipeline, and securing up to $250 million in non-dilutive financing from Sagard Healthcare Partners in March 2025, which comprises $150 million in royalty interest financing and a senior term loan to support commercialization and pipeline development. Nuvation Bio has published positive Phase 2 clinical results for safusidenib demonstrating durable responses and a high progression-free survival rate in patients with IDH1-mutant glioma. It is preparing for potential U.S. commercial launch of taletrectinib, contingent on FDA approval, supported by its strong cash position and business expansion efforts. The company targets hard-to-treat oncology indications, with a focus on innovative therapies designed to overcome resistance and improve patient outcomes globally.
Company News
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
Critical Analysis: Pathfinder Cell Therapy (OTCMKTS:PFND) and Nuvation Bio (NYSE:NUVB)
Nuvation Bio Q2 Earnings Call Highlights
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026